RP-HPLC Method for Simultaneous Estimation of Atorvastatin Calcium and Ramipril from Capsule Dosage Form

Inventi Rapid: Pharm Ana & Qual Assur 05/2010; 1(1):1-3.


INTRODUCTION Atorvastatin [R-(R*, R*)]-2-(4-fluorophenyl)-β,∂ dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenyl amino) carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt for trihydrate] is Anti-Lipidemic agent act by inhibiting HMG CoA reductase enzyme. [1] Ramipril [2S-[1[R*(R*)], 2α, 3αβ, 6αβ]]-1-[2[[1(Ethoxycarbonyl)-3-phenylpropyl] amino]-1-oxon propyl] octahydro cyclopenta [b] pyrrole-2-carboxylic acid.] is ACE inhibitor. [2-3] The combination of both drugs is used in treatment of Hypertension. Several HPLC [4-6] , HPLC [7] , Liquid Chromatography– electro Spray Ionization Tandem Mass Spectrometry [8] methods have been reported for atorvastatin alone or in combination with other drugs. [9-11] Only one UV spectroscopy i.e. derivative spectroscopy method has been reported for simultaneous estimation of atorvastatin (ATR) and ramipril (RAM). [12] The present method (Internal Standard RP-HPLC method) quantitates both drugs simultaneously without exipients interference in analysis from capsule dosage form [13] MATERIALS AND METHODS: Instrumentation: The separation of ATR and RAM was carried out on an isocratic JASCO RP-HPLC system using C18 column (150x4.6mm internal diameter, particle size 5µm).The pump used in this HPLC system was PU 2080 pump (Dual piston with gear driven pump). The 20 µl sample solutions were injected to chromatographic system using Rheodyne

Download full-text


Available from: Swapnil Jadhav, Sep 29, 2015
1 Follower
123 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: The present communication deals with the development of a new, simple, specific, sensitive, rapid and economical procedure for simultaneous estimation of atorvastatin calcium and amlodipine besylate in a combined dosage form. The method is based on the native ultraviolet absorbance maxima of the two chemotherapeutic agents. As both compounds do not interact chemically in methanol, two wavelengths 246 nm for atorvastatin calcium and 360 nm for amlodipine besylate were used. Both the drugs obeyed Beer′s law in the concentration range that was employed in the method.
    Indian Journal of Pharmaceutical Sciences 02/2007; 69(6). DOI:10.4103/0250-474X.39446 · 0.48 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A reverse phase high performance liquid chromatographic method was developed for the simultaneous estimation of atorvastatin calcium and fenofibrate in tablet formulation. The separation was achieved by Luna C18 column and methanol:acetate buffer pH 3.7 (82:18 v/v) as mobile phase, at a flow rate of 1.5 ml/min. Detection was carried out at 248 nm. Retention time of atorvastatin calcium and fenofibrate was found to be 3.02+0.1 and 9.05+0.2 min, respectively. The method has been validated for linearity, accuracy and precision. Linearity for atorvastatin calcium and Fenofibrate were in the range of 1-5 mug/ml and 16-80 mug/ml, respectively. The mean recoveries obtained for Atorvastatin calcium and fenofibrate were 101.76% and 100.06%, respectively. Developed method was found to be accurate, precise, selective and rapid for simultaneous estimation of atorvastatin calcium and fenofibrate in tablets.
    Indian Journal of Pharmaceutical Sciences 04/2008; 70(2):263-5. DOI:10.4103/0250-474X.41473 · 0.48 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A simple, precise, accurate, and rapid HPLC method has been developed, and validated for the determination of atorvastatin and amlodipine simultaneously, in combined tablet dosage form. The mobile phase used was a mixture of acetonitrile and 0.03M phosphate buffer pH 2.9 (55:45% v/v). The detection of atorvastatin and amlodipine was carried out on dual g absorbance detector at 240 nm and 362 nm, respectively. Results of the analysis were validated statistically, and by recovery studies. The proposed method can be successfully used to determine the drug contents of marketed formulation.
    Indian Journal of Pharmaceutical Sciences 02/2006; 68(2). DOI:10.4103/0250-474X.25738 · 0.48 Impact Factor
Show more